<code id='C85E6BFE96'></code><style id='C85E6BFE96'></style>
    • <acronym id='C85E6BFE96'></acronym>
      <center id='C85E6BFE96'><center id='C85E6BFE96'><tfoot id='C85E6BFE96'></tfoot></center><abbr id='C85E6BFE96'><dir id='C85E6BFE96'><tfoot id='C85E6BFE96'></tfoot><noframes id='C85E6BFE96'>

    • <optgroup id='C85E6BFE96'><strike id='C85E6BFE96'><sup id='C85E6BFE96'></sup></strike><code id='C85E6BFE96'></code></optgroup>
        1. <b id='C85E6BFE96'><label id='C85E6BFE96'><select id='C85E6BFE96'><dt id='C85E6BFE96'><span id='C85E6BFE96'></span></dt></select></label></b><u id='C85E6BFE96'></u>
          <i id='C85E6BFE96'><strike id='C85E6BFE96'><tt id='C85E6BFE96'><pre id='C85E6BFE96'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:leisure time    Page View:78
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In